Adverse event rates in clinical trials aren't just percentages-they need to account for time on treatment. Learn how the FDA now requires exposure-adjusted methods like EAIR to reveal true safety risks, and why raw percentages can mislead.
Read MoreTag: exposure-adjusted incidence rate
Understanding Adverse Event Rates: Percentages and Relative Risk in Clinical Trials
Archive
Categories
IgA Nephropathy Prognosis and Current Treatments: What You Need to Know in 2025
IgA Nephropathy prognosis and treatment have changed dramatically in 2025. Learn how KDIGO guidelines now recommend early combination therapy, the role of Nefecon and SGLT2 inhibitors, and what patients need to know about proteinuria targets and access to care.
Allergen Avoidance: Environmental Control and Home Strategies for Better Breathing
Learn practical, science-backed ways to reduce allergens in your home-dust mites, pet dander, mold, and cockroaches-and finally breathe easier without relying only on medication.
Ranitidine Explained: Uses, Risks, and Alternatives
A clear guide to ranitidine: what it does, why it was recalled, dosing basics, safety concerns, and safe alternatives for acid‑related conditions.
10 Alternatives in 2025 to Lasix for Fluid Management
Exploring ten alternatives to Lasix in 2025, this article delves into various medications that can manage fluid retention effectively. From Spironolactone to herbal options, each diuretic is explained with its benefits and downsides. We also cover potential uses, so you can understand their role in treating conditions like heart failure and hypertension. Ideal for anyone seeking a modern approach to fluid management.
First-Mover Advantage: How First Generic Drug Makers Dominate the Market
The first generic drug maker to launch after a patent expires captures up to 90% of the market - and keeps most of it for years. Here’s how the Hatch-Waxman Act creates lasting dominance.